Moomoo AI 已提取核心信息
Deborah Knobelman, Chief Financial Officer and Head of Corporate Development at Senti Biosciences, Inc., completed a stock acquisition on February 1, 2024. The transaction involved a grant of 101,000 shares of common stock at no cost. Following the transaction, Knobelman's direct holdings in the company increased to a total of 131,000 shares. The grant is part of the company's compensation structure and reflects the ongoing commitment of the executive to the company's future.
Deborah Knobelman, Chief Financial Officer and Head of Corporate Development at Senti Biosciences, Inc., completed a stock acquisition on February 1, 2024. The transaction involved a grant of 101,000 shares of common stock at no cost. Following the transaction, Knobelman's direct holdings in the company increased to a total of 131,000 shares. The grant is part of the company's compensation structure and reflects the ongoing commitment of the executive to the company's future.
森蒂生物科学公司首席财务官兼企业发展主管黛博拉·诺贝尔曼于2024年2月1日完成了股票收购。该交易涉及免费赠送10.1万股普通股。交易完成后，诺贝尔曼在该公司的直接持股量增加到总共13.1万股。该补助金是公司薪酬结构的一部分，反映了高管对公司未来的持续承诺。
森蒂生物科学公司首席财务官兼企业发展主管黛博拉·诺贝尔曼于2024年2月1日完成了股票收购。该交易涉及免费赠送10.1万股普通股。交易完成后，诺贝尔曼在该公司的直接持股量增加到总共13.1万股。该补助金是公司薪酬结构的一部分，反映了高管对公司未来的持续承诺。
有用
没用